Why the study?
Does mibefradil reduce morbidity and mortality in patients with moderate to severe congestive heart failure?
Population
2590 patients with moderate to severe congestive heart failure
Comparison
Mibefradil as adjunct to usual therapy… vs Placebo as adjunct to usual therapy
Design
RCT, randomized, double-blind
Follow-up
up to 3 years
Authors
Loading...
Mibefradil shows no mortality benefit in moderate-severe HF; challenges adjunctive use and reinforces focus on evidence-based therapies.
Does mibefradil reduce morbidity and mortality in patients with moderate to severe congestive heart failure?
Mibefradil as an adjunct therapy did not improve morbidity or mortality in patients with moderate to severe heart failure and was associated with an increased risk of death when combined with antiarrhythmics.
Levine et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: